Ranbaxy has been informed by USFDA that they can now start sourcing 6 APA from Parabolic’s Panchkula facility for Ranbaxy’s US markets. This approval came subsequent to PDL filing a DMF for USFDA approval in 2005 for its Panchkula 6 APA facility. This places PDL in a strategic position in the Pencillins business and also demonstrates PDL’s ability to put up World Class manufacturing facilities.
Category: Uncategorized